Market: NASD |
Currency: USD
Address: Ole Maaloes Vej 3
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Show more
📈 Galecto, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2024 |
- |
$0.040000 |
- |
2024-08-30 |
- |
Stock split |
|
Total Amount for 2024: $0.040000 |
📅 Earnings & EPS History for Galecto, Inc.
| Date | Reported EPS |
|---|
| 2025-08-11 | - |
| 2025-03-19 | -5 |
| 2024-11-01 | -3.39 |
| 2024-08-12 | -5 |
| 2024-04-29 | -5 |
| 2024-03-08 | -4.76 |
| 2023-11-06 | -4.99 |
| 2023-07-31 | -10.25 |
| 2023-04-28 | -12.75 |
| 2023-03-09 | -13.75 |
| 2022-11-08 | -13.5 |
| 2022-07-29 | -16.75 |
| 2022-04-29 | -16.75 |
| 2022-02-17 | -13.25 |
| 2021-11-04 | -12.5 |
| 2021-08-05 | -12.25 |
| 2021-05-04 | -13.25 |
| 2021-03-29 | -10.25 |
| 2020-12-11 | -1381.25 |
📰 Related News & Research
No related articles found for "galecto inc".
